Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.
about
Interleukin-15 biology and its therapeutic implications in cancerThe role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic useNK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyDeveloping Combined HIV Vaccine Strategies for a Functional CureTargeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem CellsThe shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapyIntramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cellsRedistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against RhabdomyosarcomaExpansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cellsCharacterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer.Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency.Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1NK cells: immune cross-talk and therapeutic implications.IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral bloodIncreased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemiaTransmembrane-Bound IL-15-Promoted Epithelial-Mesenchymal Transition in Renal Cancer Cells Requires the Src-Dependent Akt/GSK-3β/β-Catenin Pathway.Exercise-stimulated interleukin-15 is controlled by AMPK and regulates skin metabolism and aging.IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum.Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal ModelsInterleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphomaInsulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15RαIntraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myelomaIdentification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposureHost genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia.The new normal: immunomodulatory agents against sepsis immune suppression.Use of allogeneic NK cells for cancer immunotherapy.Immunotherapeutic applications of IL-15.Current strategies in immunotherapy for acute myeloid leukemia.IL-15 Agonists: The Cancer Cure Cytokine.Clinical utility of natural killer cells in cancer therapy and transplantation.Assessment of the metabolism of therapeutic proteins and antibodies.Interleukin-15 in the treatment of cancer.
P2860
Q24595605-06B1556A-7BF5-49BF-8AAE-9C23E05A21A8Q24599103-438B62D1-2FFB-45B2-AF20-459EBA8BCD4BQ26797345-4CB62DE8-4FF4-44ED-960E-8303E77FC1CCQ26998898-CEF84875-4E25-4513-B5AA-42335C0AF2A0Q28078154-69186867-8E95-40AC-8AA5-B95349AC6558Q28088784-346CB33A-2FA3-42EC-B98D-E4CAEA31A8E5Q28652428-540B86CD-88FB-4453-A64A-9AEE7F2C1917Q33418729-29024A34-A9AD-441A-ABAF-44DCD02E1A82Q33434322-0E671324-B4D4-43C2-A62A-637097E01D46Q33785788-DB3552C4-9592-4BF8-A4D9-3218BC9F9F23Q33905311-E68580D5-97EA-4073-A16C-3EFA609AFB5EQ34539858-DADF41AC-23BA-4FBB-AAD9-519B71ABC835Q34708192-13728552-51C8-4C30-A51C-4BC117BAC7E5Q34936507-CB138CB1-4800-4D72-AD6D-F50C7026E1D1Q35060701-00CE1D7C-8532-4777-BC4B-3B7AC1A3B14CQ35591444-9049B20E-0F0D-444C-83C2-40F4DD0154F5Q35631305-868D2E92-820B-4B3D-9141-4325A9AEDF9BQ35651700-9282F306-2CED-4BAE-A7CF-5587C37F7982Q35745099-2100ADA8-FB50-4C1E-989F-1C5585EE4730Q35935174-5D242A97-BFAC-4C62-A19D-A6335D313147Q35979037-2A536E68-0B70-412C-AEC0-43EAC01D6536Q36016369-533721C2-E829-4E72-9E82-1AD9A6EF25DCQ36079820-33FF013D-2461-4B13-9EE5-1F93ACE4B76CQ36416387-AFF0F792-F63E-4C58-83B9-50000F0361D4Q36436914-0988D2E4-4A34-4E28-9850-EDCF8A52DFC7Q36956269-FEF9918B-FB3F-4008-84F5-DB585D6DDDD1Q37103886-85074EDC-59F3-4ED6-81D3-FA59A97B39CDQ37178190-65017A58-9612-4F1C-A83E-66E0378CD4E2Q37261189-6BB8642D-EF15-4EB5-92EE-A6386C2E3369Q37557639-C123380A-ED38-4835-99C6-3CD07EF2C567Q37580158-777AAD0E-D07F-4364-943D-80B63F950F8DQ37650740-0CD3B81C-9698-4EA7-A774-B3196791FC15Q37686624-59C8F734-1BFA-4936-AC35-BCBC20EB952DQ37957140-5F7434F6-85F7-44E4-BEF4-7B632A05EBB6Q38050510-D8B3CDCF-9EEB-4E24-A1A6-01581C87ECF1Q38068967-9F011C84-7192-44B4-8C4B-BFC496F09C4FQ38192628-69DAD363-58CA-4E54-AF28-8D2A8E3421B5Q38195120-30133400-85FB-4447-9A6B-8F670D2E9236Q38217623-3326F6F9-8E14-4F08-989B-3E8B981C4E5DQ38264072-B966C0AE-68ED-4F5C-988B-7A83E4D3030D
P2860
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Safety (toxicity), pharmacokin ...... uman IL-15 in rhesus macaques.
@ast
Safety (toxicity), pharmacokin ...... uman IL-15 in rhesus macaques.
@en
type
label
Safety (toxicity), pharmacokin ...... uman IL-15 in rhesus macaques.
@ast
Safety (toxicity), pharmacokin ...... uman IL-15 in rhesus macaques.
@en
prefLabel
Safety (toxicity), pharmacokin ...... uman IL-15 in rhesus macaques.
@ast
Safety (toxicity), pharmacokin ...... uman IL-15 in rhesus macaques.
@en
P2093
P2860
P1433
P1476
Safety (toxicity), pharmacokin ...... uman IL-15 in rhesus macaques.
@en
P2093
Bonita R Bryant
Carolyn K Goldman
Enrico Lugli
H Clifford Lane
Jason L Yovandich
Jean M Decker
John M Pletcher
Liyanage P Perera
Mario Roederer
Michael C Sneller
P2860
P304
P356
10.1182/BLOOD-2010-10-311456
P407
P577
2011-03-08T00:00:00Z